Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...
Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results